STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMO
  4. [Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity

Thermo Fisher (NYSE: TMO) CEO exercises options, sells 20K shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

THERMO FISHER SCIENTIFIC INC. (TMO) reported insider transactions by Chairman & CEO Marc N. Casper involving option exercises and share sales. On August 20 and 21, 2026, he exercised stock options for a total of 20,000 shares of common stock at an exercise price of $309.63 per share. On the same dates, he sold an aggregate of 20,000 shares of common stock in multiple transactions at weighted average prices generally between the mid‑$620s and low‑$630s per share, as described in the sale footnotes. The transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted on April 27, 2026. Indirect holdings include 11,300 shares held by the Alison Casper 2020 Irrevocable Trust and 5,000 shares held by the MNC 2020 Irrevocable Trust, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider CASPER MARC N
Role Chairman & CEO
Sold 20,000 shs ($12.56M)
Approx. gross sale proceeds $12.56M
Approx. exercise cost $6.19M
Approx. pre-tax spread $6.37M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F16 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $309.63 $3.10M
Sale Common Stock F1, F10 2,727 $625.46 $1.71M
Sale Common Stock F1, F11 3,014 $626.51 $1.89M
Sale Common Stock F1, F12 1,791 $627.39 $1.12M
Sale Common Stock F1, F13 2,147 $628.61 $1.35M
Sale Common Stock F1, F14 321 $629.10 $202K
Exercise Stock Option (Right to Buy) F16 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $309.63 $3.10M
Sale Common Stock F1, F2 909 $625.45 $569K
Sale Common Stock F1, F3 821 $626.83 $515K
Sale Common Stock F1, F4 1,314 $627.66 $825K
Sale Common Stock F1, F5 2,601 $628.82 $1.64M
Sale Common Stock F1, F6 1,250 $629.85 $787K
Sale Common Stock F1, F7 1,035 $630.87 $653K
Sale Common Stock F1, F8 1,430 $632.01 $904K
Sale Common Stock F1, F9 560 $632.94 $354K
Sale Common Stock F1 80 $633.99 $51K
holding Common Stock F15 -- -- --
holding Common Stock F15 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 275 shares (Direct); Common Stock — 123,925.358 shares (Direct); Common Stock — 11,300 shares (Indirect, By Alison Casper 2020 Irrevocable Trust); Common Stock — 5,000 shares (Indirect, By MNC 2020 Irrevocable Trust)
Footnotes (16)
  1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive.
  10. F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive.
  11. F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive.
  12. F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive.
  13. F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive.
  14. F14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive.
  15. F15. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
  16. F16. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
Options exercised 20,000 shares of common stock Exercised via stock options on August 20 and 21, 2026
Option exercise price $309.63 per share Conversion or exercise price for the stock options exercised
Shares sold 20,000 shares of common stock Aggregate shares sold in multiple transactions on August 20–21, 2026
Representative sale price $625.45 per share Weighted average price for a 909‑share sale on August 20, 2026
Highest referenced price range $632.60 to $633.32 per share Price range for one group of sales noted in footnote F9
Indirect trust holding – Alison Casper 2020 Irrevocable Trust 11,300 shares of common stock Indirect ownership with beneficial ownership disclaimed except for pecuniary interest
Indirect trust holding – MNC 2020 Irrevocable Trust 5,000 shares of common stock Indirect ownership with beneficial ownership disclaimed except for pecuniary interest
Rule 10b5-1 plan adoption date April 27, 2026 Date the trading plan governing these transactions was adopted
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of the securities reported herein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
irrevocable trust financial
"By Alison Casper 2020 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

FAQ

What did TMO Chairman & CEO Marc N. Casper do in this Form 4?
Marc N. Casper exercised stock options for 20,000 shares of Thermo Fisher common stock at $309.63 per share and sold 20,000 shares of common stock in multiple transactions on August 20–21, 2026.

At what prices were the Thermo Fisher (TMO) shares sold in these transactions?
The 20,000 shares of Thermo Fisher common stock were sold at weighted average prices, with individual transactions occurring in ranges generally between about $625.00 and $633.99 per share, as detailed in multiple footnotes describing the specific price ranges.

Were Marc N. Casper’s TMO trades under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions in this Form 4 were effected pursuant to a Rule 10b5‑1 trading plan adopted by Marc N. Casper on April 27, 2026.

How many Thermo Fisher (TMO) options did Marc N. Casper exercise?
He exercised stock options covering a total of 20,000 shares of Thermo Fisher common stock, in two tranches of 10,000 shares each on August 20, 2026 and August 21, 2026, at an exercise price of $309.63 per share.

What indirect Thermo Fisher (TMO) holdings are reported for Marc N. Casper?
The filing lists 11,300 shares held by the Alison Casper 2020 Irrevocable Trust and 5,000 shares held by the MNC 2020 Irrevocable Trust. A footnote states Marc N. Casper disclaims beneficial ownership except to the extent of any pecuniary interest.

When did the options exercised by Marc N. Casper in TMO vest and expire?
A footnote states the option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024, and the Form 4 shows an expiration date of February 25, 2027 for the reported option grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CASPER MARC N
(Last)(First)(Middle)
168 THIRD AVENUE
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/20/2026M10,000A$309.63133,925.358D
Common Stock08/20/2026S(1)909D$625.45(2)133,016.358D
Common Stock08/20/2026S(1)821D$626.83(3)132,195.358D
Common Stock08/20/2026S(1)1,314D$627.66(4)130,881.358D
Common Stock08/20/2026S(1)2,601D$628.82(5)128,280.358D
Common Stock08/20/2026S(1)1,250D$629.85(6)127,030.358D
Common Stock08/20/2026S(1)1,035D$630.87(7)125,995.358D
Common Stock08/20/2026S(1)1,430D$632.01(8)124,565.358D
Common Stock08/20/2026S(1)560D$632.94(9)124,005.358D
Common Stock08/20/2026S(1)80D$633.99123,925.358D
Common Stock08/21/2026M10,000A$309.63133,925.358D
Common Stock08/21/2026S(1)2,727D$625.46(10)131,198.358D
Common Stock08/21/2026S(1)3,014D$626.51(11)128,184.358D
Common Stock08/21/2026S(1)1,791D$627.39(12)126,393.358D
Common Stock08/21/2026S(1)2,147D$628.61(13)124,246.358D
Common Stock08/21/2026S(1)321D$629.1(14)123,925.358D
Common Stock11,300IBy Alison Casper 2020 Irrevocable Trust(15)
Common Stock5,000IBy MNC 2020 Irrevocable Trust(15)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$309.6308/20/2026M10,000 (16)02/25/2027Common Stock10,000$010,275D
Stock Option (Right to Buy)$309.6308/21/2026M10,000 (16)02/25/2027Common Stock10,000$0275D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive.
15. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
16. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
Remarks:
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper08/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR